Thyroidal 125I monitoring system using a survey meter for 125I.

Autoradiographic estimation of red cell D antigen content using 125I-anti-D and 125I membrane labeling.

Advantages of using thin sodium iodide detectors for thyroid monitoring of personnel working with 125I.

Measurements of neck count-rates for personnel who regularly iodinated proteins with 125I showed that, generally, count rates were higher after iodination than before. The major pathway for the intake of 125I during iodination was through skin that was exposed to the free-iodine atmosphere of the fume hood. Neck count-rates were measured in 34 other subjects who were working with 125I. The rate...

Characterization of (S)-des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a selective high-affinity radioligand for 5-hydroxytryptamine3 receptors.

The 5-hydroxytryptamine(HT)3 receptor subtype is present in the central nervous system (CNS) in low abundance, and few selective radiolabeled antagonists with high specific activity are available to study these sites. DAIZAC [desamino-3-iodo-(S)-zacopride; (S)-5-chloro-3-iodo-2-methoxy-N-(1-azobicyclo-[2.2. 2]oct-3-yl)benzamide] is a compound with high affinity and selectivity for the 5-HT3 rec...

Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy

BACKGROUND Complete resection of pelvic bone tumors, especially recurrent and metastatic ones, is often impossible to achieve using conventional surgery. This study aimed to assess the benefits and adverse effects of computed tomography (CT)-guided radioiodine (125I) brachytherapy for inoperable recurrent and metastatic bone tumors of the pelvis. METHODS This was a retrospective study of 22 p...

125I brachytherapy for localized prostate cancer: a single institution experience.

AIMS AND BACKGROUND To evaluate the clinical outcome of a cohort of localized prostate cancer patients treated with 125I permanent brachytherapy at the University of Turin. METHODS AND STUDY DESIGN A retrospective analysis was carried out on 167 consecutive patients with early stage prostate adenocarcinoma who underwent 125I brachytherapy between January 2003 and December 2010. A minimum foll...